cute promyelocytic leukemia (APL) is a variant of AML characterized by t (15; 17). The discovery of the molecular pathogenesis has led to the first targeted therapy for acute leukemia: all-trans retinoic acid (ATRA). ATRA is usually associated to anthracycline-based chemotherapy obtaining high response rates, but some potential longterm sequelae are described [1]. The introduction of arsenic trioxide (ATO)[2] and ATRA was compared to standard chemotherapy in a pivotal trial with excellent results both in terms of complete
Sica, S., reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxite plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid, <<LEUKEMIA & LYMPHOMA>>, 2019; (60): 1328-1330 [http://hdl.handle.net/10807/169715]
reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxite plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid
Sica, Simona
Membro del Collaboration Group
2019
Abstract
cute promyelocytic leukemia (APL) is a variant of AML characterized by t (15; 17). The discovery of the molecular pathogenesis has led to the first targeted therapy for acute leukemia: all-trans retinoic acid (ATRA). ATRA is usually associated to anthracycline-based chemotherapy obtaining high response rates, but some potential longterm sequelae are described [1]. The introduction of arsenic trioxide (ATO)[2] and ATRA was compared to standard chemotherapy in a pivotal trial with excellent results both in terms of complete
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
